ANAPTYSBIO, INC

ANAB · Nasdaq · SIC 2834: Pharmaceutical Preparations
171
SEC Filings

Business Summary

AnaptysBio is a clinical-stage biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. Its pipeline includes rosnilimab (pathogenic T cell depleter for rheumatoid arthritis), ANB033 (CD122 antagonist for celiac disease and eosinophilic esophagitis), and ANB101 (BDCA2 modulator). The company also out-licensed dostarlimab (Jemperli) to GSK and imsidolimab to Vanda Pharmaceuticals, generating milestone and royalty revenue.

Next Earnings

Q2 FY2026 — expected 2026-09-17

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionANABdiscussed_in_filing Healthcare & Bio
topic_mentionANABdiscussed_in_filing Healthcare & Bio
topic_mentionANABdiscussed_in_filing Healthcare & Bio
topic_mentionANABdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-032025-12-310001193125-26-088290EDGAR80K words
2025-02-272024-12-310001370053-25-000024EDGAR—
2024-03-112023-12-310001370053-24-000011EDGAR—
2023-03-012022-12-310001370053-23-000020EDGAR—
2022-03-072021-12-310001370053-22-000009EDGAR—
2021-02-252020-12-310001370053-21-000019EDGAR—
2020-03-022019-12-310001370053-20-000009EDGAR—
2019-02-282018-12-310001370053-19-000006EDGAR—
2018-03-052017-12-310001370053-18-000014EDGAR—
2017-03-082016-12-310001564590-17-003710EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-042025-09-300001370053-25-000089EDGAR47K words
2025-08-062025-06-300001370053-25-000064EDGAR—
2025-05-052025-03-310001370053-25-000046EDGAR—
2024-11-052024-09-300001370053-24-000054EDGAR—
2024-08-052024-06-300001370053-24-000041EDGAR—
2024-05-092024-03-310001370053-24-000027EDGAR—
2023-11-022023-09-300001370053-23-000065EDGAR—
2023-08-072023-06-300001370053-23-000049EDGAR—
2023-05-112023-03-310001370053-23-000040EDGAR—
2022-11-082022-09-300001370053-22-000066EDGAR—
2022-08-082022-06-300001370053-22-000043EDGAR—
2022-05-042022-03-310001370053-22-000032EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-270001193125-26-127783EDGAR22K words
2026-03-030001193125-26-088239EDGAR—
2026-01-090001370053-26-000002EDGAR—
2025-11-260001370053-25-000103EDGAR—
2025-11-210001370053-25-000097EDGAR—
2025-11-210001370053-25-000096EDGAR—
2025-11-100001370053-25-000091EDGAR—
2025-11-040001370053-25-000088EDGAR—
2025-10-140001370053-25-000083EDGAR—
2025-09-290001370053-25-000081EDGAR—

171 total filings indexed. 139 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

autoimmune-diseases inflammatory-diseases rheumatology gastroenterology dermatology respiratory immuno-oncology

Company Identity

CIK0001370053
TickerANAB
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: e2b8827c08c61df28b85bba5ee1748df61e053e7cb1ccc784b8dbc76c7a26fc3
parent: cad7e449a8bd5d8ddd2ec09c7ad78682155af7c75794a1f22d3f28632c091980
content hash: b69ae9e30b66f890b02183544980caf174d1c85941ac779b2a552360fc88aa2c
signed: 2026-04-13T04:43:39.050Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf